as seen in Targeting Trends Newsletter, Jul-Aug-Sep 2008

ATS recently licensed SP-SAP for development as a chronic pain therapeutic in humans. Much progress has been made in the past three months to prepare the pre-IND package for a meeting with the FDA. This meeting has been requested and the FDA has assigned a meeting date of October 2nd. The purpose of this meeting will be to present data and determine the next steps for moving SP-SAP into human clinical trials.

Part of the data that will be presented at the pre-IND meeting will be from the veterinary clinical trial now going on with SP-SAP in companion dogs with bone cancer. We are very encouraged by the mid-term results of this trial and are hopeful that we can find a veterinary pharmaceutical company that will market this chronic pain drug for use in animals.

As part of the veterinary development, we hope to begin a trial in cats in the near future. Felines have a unique need because they are intolerant to treatment with standard non-steroidal, non-inflammatory medications, due to the way their livers function.

Check the October issue for more updates on SP-SAP.

Home | Tutorial | Catalog | News | References | Search | Contact | Site Map
ADVANCED TARGETING SYSTEMS